MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

Simulations Plus Inc

Cerrado

SectorSanidad

14.27 1.64

Resumen

Variación precio

24h

Actual

Mínimo

14.18

Máximo

14.64

Métricas clave

By Trading Economics

Ingresos

3.9M

4.5M

Ventas

5.9M

24M

BPA

0.35

Rentabilidad por dividendo

0.48

Margen de beneficios

18.669

Empleados

212

EBITDA

4.9M

7.2M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+66.43% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.38%

Próximas Ganancias

13 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

11M

262M

Apertura anterior

12.63

Cierre anterior

14.27

Noticias sobre sentimiento de mercado

By Acuity

13%

87%

19 / 348 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 abr 2026, 20:26 UTC

Adquisiciones, fusiones, absorciones

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 abr 2026, 18:15 UTC

Noticias de Eventos Importantes

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 abr 2026, 16:49 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 abr 2026, 16:49 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 abr 2026, 22:58 UTC

Ganancias

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 abr 2026, 21:32 UTC

Charlas de Mercado

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 abr 2026, 21:22 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 abr 2026, 21:22 UTC

Charlas de Mercado

Moody's Downgrades Belgium to A1 -- Market Talk

17 abr 2026, 20:52 UTC

Ganancias

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 abr 2026, 20:50 UTC

Charlas de Mercado
Ganancias
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

17 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 abr 2026, 20:29 UTC

Ganancias

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 abr 2026, 20:11 UTC

Adquisiciones, fusiones, absorciones

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 abr 2026, 19:34 UTC

Charlas de Mercado
Ganancias
Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

17 abr 2026, 19:34 UTC

Charlas de Mercado
Ganancias
Adquisiciones, fusiones, absorciones

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 abr 2026, 19:31 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 abr 2026, 19:26 UTC

Charlas de Mercado

U.S. Natural Gas Futures Edge Up -- Market Talk

17 abr 2026, 19:21 UTC

Charlas de Mercado

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 abr 2026, 19:15 UTC

Charlas de Mercado

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 abr 2026, 19:07 UTC

Charlas de Mercado

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 abr 2026, 18:57 UTC

Noticias de Eventos Importantes

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 abr 2026, 18:53 UTC

Adquisiciones, fusiones, absorciones

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 abr 2026, 18:53 UTC

Adquisiciones, fusiones, absorciones

UCB 2026 Rev Guidance Unchanged

17 abr 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 abr 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 abr 2026, 18:14 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 abr 2026, 18:00 UTC

Noticias de Eventos Importantes

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 abr 2026, 18:00 UTC

Noticias de Eventos Importantes

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 abr 2026, 17:31 UTC

Charlas de Mercado
Noticias de Eventos Importantes

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 abr 2026, 17:26 UTC

Charlas de Mercado
Ganancias

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

66.43% repunte

Estimación a 12 Meses

Media 23.5 USD  66.43%

Máximo 31 USD

Mínimo 16 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

19 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat